Debbie Rigby takes a look at the latest in research news
In this population-based nested case-control study, no significant associations between current, recent, or past use of inhaled corticosteroids and first fracture after asthma diagnosis were observed in children with moderate persistent asthma. However, systemic corticosteroids were associated with a 17% increased risk of fractures.
JAMA Pediatr. Published online November 13, 2017.
LAMA/LABA combinations are recommended COPD patients with persistent symptoms, COPD patients with further exacerbations on LAMA therapy alone and for patients with or without combination with inhaled corticosteroids. LAMA/LABA combinations have been shown to improve lung function, lung hyperinflation, exercise capacity, quality of life and exacerbation frequency thereby slowing disease progression in COPD.
Expert Opinion on Pharmacotherapy, 2017.
Analysis of the EMPA-REG OUTCOME trial shows no association between empagliflozin and the risk of lower limb amputations. This result contrasts with results from the CANVAS study, where canagliflozin was associated with a 41% increased risk of lower limb amputation in patients with type 2 diabetes and high cardiovascular risk. The EMPA-REG OUTCOME trial was conducted in people type 2 diabetes and established cardiovascular disease.
Diabetes Care 2017 Nov; dc171551.
A systematic review and meta-analysis of RCTs has concluded that transdermal oestradiol and progestogen is the most effective treatment for vasomotor symptoms of menopause. Isoflavones and black cohosh were more effective than placebo, although not significantly better than transdermal oestradiol and progestogen. SSRIs and SNRIs were found to be ineffective.